Several analyses of the international randomized phase 3 Breast Cancer Trials of Oral Everolimus-2 (BOLERO-2) plus exemestane versus exemestane alone for the treatment of postmenopausal women with HER2-negative, hormone receptor-positive (HR+) advanced breast cancer, including updated efficacy results, health-related quality of life (QOL), effects in Asian populations, and safety in women over 65 years of age, were explored in presentations at the 2012 Annual Meeting of the American Society of Clinical Oncology.
Physicians, nurse practitioners, physician assistants, nurses, and other healthcare providers who manage patients with breast cancer.
After participating in this educational activity, participants should be better able to:
Recognize hyperactivation of the PI3K/AKT/mammalian target of rapamycin (mTOR) signaling pathway in endocrine-resistant breast cancer cells.
Assess the efficacy of the mTOR inhibitor everolimus in combination with the steroidal aromatase inhibitor exemestane in patients with HR+ advanced breast cancer.
Click Next to begin the activity.